Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06237777
PHASE1

A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

Sponsor: Wang Min

View on ClinicalTrials.gov

Summary

This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.

Official title: An Open, Dose-escalation Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients in China

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2024-05

Completion Date

2026-01

Last Updated

2024-04-30

Healthy Volunteers

No

Interventions

GENETIC

SKG0106 intravitreal injection dose level 1, 2 or 3

SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.

Locations (2)

Peking Union Medical College Hospital

Beijing, China

Eye & ENT Hospital of Fudan University

Shanghai, China